A-366 is a novel highly potent, selective and cell permeable G9a/GLP histone lysine methyltransferase inhibitor with an IC50~3.3 nM. It has selectivity > 1000-fold over 21 other methyltransferases. A-366 has been shown to inhibit H3K9 methylation in prostate cancer PC3 cells with an IC50?of 100 nM and exhibits minimal cellular toxicity compared with previous quinazoline-based probes, such as BIX-01294 and UNC0638.
?
How to Use:
?
In vitro:? A-366 was used at 1 μM in vitro and cellular assays.
?
In vivo:?n/a
?
Reference:
?
1. Sweis RF, et al. Discovery and development of potent and selective inhibitors of histone methyltransferase g9a. (2014) ACS Med Chem Lett. 5(2):205-9.
2.?http://www.thesgc.org/chemical-probes/A-366
Products are for research use only. Not for human use.